BFRI
Biofrontera Inc.
BFRI's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over BFRI overall, supported by lower modeled downside and stronger fundamentals.
BFRI Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Under pressure | |
| Unavailable |
BFRI's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
BFRI PE Valuation
BFRI has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 3.7x next year's earnings.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
BFRI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect BFRI to return to profit, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
BFRI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.25 | — |
| Q3 2024 | -$1.33 | +$18.59 |
| Q2 2024 | -$4.99 | +$12.40 |
| Q1 2024 | -$12.17 | -$1.06 |
| Q4 2023 | -$14.89 | -2541% |
LLY has the stronger earnings trend. Trailing diluted EPS is down 109% for BFRI versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
BFRI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $12M | +33% |
| Q1 2026 | $10.1M | +17% |
| Q4 2025 | $17.1M | +36% |
| Q3 2025 | $7M | -22% |
| Q2 2025 | $9M | +15% |
| Q1 2025 | $8.6M | +8.5% |
| Q4 2024 | $12.6M | +19% |
| Q3 2024 | $9M | +1.3% |
BFRI's revenue is growing: $12M last quarter, up 33% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -4.4% | +52 points |
| Q1 2026 | -43% | +10 points |
| Q4 2025 | 27% | +40 points |
| Q3 2025 | -90% | -35 points |
| Q2 2025 | -56% | +8.4 points |
| Q1 2025 | -53% | +16 points |
| Q4 2024 | -14% | +23 points |
| Q3 2024 | -55% | -3.1 points |
BFRI's operating margin was −4.4% last quarter, up 52 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over BFRI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over BFRI on profitability, with a higher operating margin.
BFRI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$1.7M | +$1.4M |
| Q1 2026 | -$75K | +$4M |
| Q4 2025 | -$2.4M | -$1.4M |
| Q3 2025 | -$3.8M | -$2.6M |
| Q2 2025 | -$3M | +$1.6M |
| Q1 2025 | -$4.1M | -$738K |
| Q4 2024 | -$1M | +$7.8M |
| Q3 2024 | -$1.2M | +$796K |
BFRI has burned cash in almost every quarter: −$8M over the past year, against −$9M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over BFRI on cash generation, producing positive trailing cash flow while its opponent burns cash.
BFRI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +11% | +1.2M shares |
| 1 year | +38% | +3.6M shares |
| 3 years | +868% | +11.6M shares |
| 5 years | +2128% | +12.3M shares |
BFRI has 13M diluted shares, up 38% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over BFRI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
BFRI Net Leverage
BFRI's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
BFRI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.2 | Neutral |
| Stochastic | 10.9 | Oversold |
BFRI's weekly RSI is 44 (neutral) and its Stochastic is 11 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
BFRI PE vs Healthcare Sector
BFRI has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
BFRI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.92 | 1.1% above |
| 20 week MA | $1.15 | 19% below |
| 50 week MA | $1.00 | 7% below |
| 100 week MA | $0.95 | 2.1% below |
| 200 week MA | $3.17 | 71% below |
BFRI has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 71% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over BFRI on trend strength, trading above more of its moving averages.
BFRI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $88.2 | $263.4 | +198% |
| 2022 | $263.4 | $18.6 | -93% |
| 2023 | $18.6 | $2.77 | -85% |
| 2024 | $2.77 | $1.11 | -60% |
| 2025 | $1.11 | $0.72 | -35% |
| 2026 YTD | $0.72 | $0.93 | +29% |
BFRI has finished four years in a row lower, and it's up 29% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over BFRI on returns for 2026, with the stronger performance.